Skip to content

Twist Bioscience

US · TWST #1258 by market cap Listed 2018
103.32 -8.30 -7.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:52

Valuation each multiple against its own 5-year range

P/B ratio 7.71 Expensive vs history 88th percentile
5-year average 5.18 · #450 of 511 in Biotechnology
P/E ratio -49.67 Cheap vs history 10th percentile
5-year average -18.85 · forward -76.22
P/S ratio 14.91 Expensive vs history 84th percentile
5-year average 9.97 · forward 12.32 · #209 of 392 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Twist Bioscience (TWST) 6.85B -49.67 7.71 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value120.58 Economic moatNone UncertaintyHigh

Trading 16.7% below Morningstar's fair value estimate.

Fair value

Twist Bioscience Corp is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $120.58 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's balance sheet bolsters our valuation estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 5.9 sits in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -1.8%, for example, falls in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:52:04 · For reference only, not investment advice and not tailored to your situation.

Twist Bioscience discussion 0 comments

Add a comment